Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Detection of K14 in Bladder Cancer With a Non Invasive Technique

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02027649
Recruitment Status : Terminated (Absence of positive results)
First Posted : January 6, 2014
Last Update Posted : July 21, 2017
Sponsor:
Information provided by (Responsible Party):
Juan Francisco Delgado de la Poza, Corporacion Parc Tauli

Brief Summary:
By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker for this cancer.

Condition or disease
Bladder Cancer

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 400 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.
Actual Study Start Date : January 2014
Actual Primary Completion Date : July 2014
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Group/Cohort
Bladder cancer
Patients who suffered a bladder cancer
Control group
Patients with urologic diseases of non tumoral origin



Primary Outcome Measures :
  1. Keratin 14 [ Time Frame: At the time of study entry ]

Biospecimen Retention:   Samples Without DNA
Urine


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital patients.
Criteria

Inclusion Criteria:

  • Bladder cancer

Exclusion Criteria:

  • Inability to sign the informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02027649


Locations
Layout table for location information
Spain
Corporació Sanitària i Universitària Parc Taulí
Sabadell, Barcelona, Spain, 08208
Sponsors and Collaborators
Corporacion Parc Tauli

Additional Information:

Layout table for additonal information
Responsible Party: Juan Francisco Delgado de la Poza, Medical Doctor, Corporacion Parc Tauli
ClinicalTrials.gov Identifier: NCT02027649     History of Changes
Other Study ID Numbers: K14 in bladder cancer
CIR2013 ( Other Grant/Funding Number: Fundació Parc Taulí )
First Posted: January 6, 2014    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: July 2017

Keywords provided by Juan Francisco Delgado de la Poza, Corporacion Parc Tauli:
Bladder cancer
Keratin 14
Pronostic marker
Diagnostic marker
Noninvasive technique

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases